Brain zapping for meth cravings? study pulled before it started
NCT ID NCT06695637
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if a non-invasive brain stimulation technique called TMS could help people with methamphetamine use disorder control their cravings. Researchers planned to recruit 40 adults living in a residential treatment program and give some real stimulation and others a sham treatment. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial Magnetic Stimulation (TMS) - a non-invasive brain stimulation technique
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 1 week at study enrollment * Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study. * Able to provide written consent and comply with study procedures. * Meets the DSM-V MINI diagnostic criteria for methamphetamine use disorder (MUD). * Subjects may have current comorbid drug use, but one of their major substance use disorder diagnosis needs to be methamphetamine use. Potential subjects will not be excluded for being on medication-assisted treatments (MATs), such as those used to treat substance use disorders. Exclusion Criteria: * Any contraindications for MRI scanning (up to the discretion of MIDB staff: metal implants, pacemakers or any other implanted electrical device, injury with metal, braces, dental implants, non-removable body piercings, pregnancy, breathing or moving disorder, moderate to severe heart disease). * Any medical condition or treatment with neurological sequelae (i.e., stroke, tumor, HIV, intracranial lesions) * Having epilepsy, a personal history of a seizure (beyond fever or withdrawal or medical induced seizure), or individuals with a family history of clinically proven epilepsy disorder in a first degree relative * Over 9 months of abstinence from substance use * A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI) * Presence of a condition that would render study measures difficult or impossible to administer or interpret * Age outside the range of 22 to 65 * Entrance to the treatment program under a court mandate. (i.e., legally incarcerated) * History of ECT or cortical energy exposure within the past 6 months, including participation in any other neuromodulation studies * Being pregnant. For females of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline will be necessary for inclusion. * Having current active suicidal ideations reported in baseline psychiatry interview * Having active bipolar disorder (with a risk of mania) * Using medications that significantly increase risk of seizure for this study based on the clinical judgement of the study's medical team such as immediate release bupropion (Wellbutrin IR), stimulants, and tramadol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Methamphetamine use disorders are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise boost brain and body health during opioid treatment?
- Peer mentors may help young adults stick with addiction treatment
- Can cramming PTSD therapy into a few weeks help veterans cut substance use?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a family talk program shield teens from substance use?
- Can online training equip therapists to tackle PTSD and addiction?